[1]任春艳,方瑶,李倩,等.类鼻疽杆菌毒素分子BLF1的重组表达及生物学活性[J].第三军医大学学报,2016,38(11):1215-1219.
 Ren Chunyan,Fang Yao,Li Qian,et al.Recombinant expression and biological characterization of Burkholderia pseudomallei toxin BLF1[J].J Third Mil Med Univ,2016,38(11):1215-1219.
点击复制

类鼻疽杆菌毒素分子BLF1的重组表达及生物学活性(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第11期
页码:
1215-1219
栏目:
专题报道
出版日期:
2016-06-15

文章信息/Info

Title:
Recombinant expression and biological characterization of Burkholderia pseudomallei toxin BLF1
作者:
任春艳方瑶李倩胡艺马腾飞胡治强袁顺翎周杰汪黎鸿何晓奕毛旭虎
第三军医大学西南医院医学检验系临床微生物及免疫学教研室
Author(s):
Ren Chunyan Fang Yao Li Qian Hu Yi Ma Tengfei Hu Zhiqiang Yuan Shunling Zhou Jie Wang Lihong He Xiaoyi Mao Xuhu

Department of Clinical Microbiology and Immunology, Faculty of Medical Laboratory Sciences, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China

关键词:
类鼻疽杆菌BLF1蛋白毒素细胞毒性
Keywords:
Burkholderia pseudomallei BLF1 protein toxin cytotoxicity
分类号:
R378.99; R392-33; R392.7
文献标志码:
A
摘要:

目的      重组、表达类鼻疽杆菌毒素BLF1并研究其生物学活性。      方法      运用DNA重组技术,以pGEX为表达系统在大肠杆菌中表达BLF1蛋白;以纯化重组蛋白rBLF1免疫新西兰大白兔,获得抗rBLF1血清,Western blot及ELISA鉴定抗血清;不同浓度rBLF1蛋白腹腔注射BALB/c小鼠,观察小鼠生存率; A549细胞模型中,通过CCK-8实验研究目的蛋白的细胞毒性效应及抗体阻断作用。      结果      从类鼻疽杆菌基因组DNA中PCR得到了BLF1目的基因,连接到pGEX-6p-2质粒,经双酶切及测序表明重组质粒构建成功。GST-BLF1蛋白经诱导表达、酶切纯化得到了相对分子质量为23×103的高纯度rBLF1,免疫家兔抗血清ELISA效价达1∶1 280 000,Western blot鉴定在目的蛋白位置处出现特异印记条带。重组rBLF1蛋白腹腔注射BALB/c小鼠,小鼠死亡率与蛋白剂量呈正相关。rBLF1蛋白能明显杀伤A549细胞,抗体可有效阻断其杀伤作用。      结论      成功重组表达了具有生物活性的rBLF1,该蛋白具有明显杀伤A549肿瘤细胞的作用,同时能够导致小鼠死亡但表现出一定耐受性。

Abstract:

Objective       To express recombinant Burkholderia pseudomallei toxin BLF1 and observe its biological characterization.       Methods       The pGEX expression system was adopted to express recombinant BLF1 protein through recombinant DNA technology. The target protein was used to immunize New Zealand white rabbits, and the immunogenicity of the expressed protein was identified by ELISA and Western blotting. The survival rate of BALB/c mice was observed after intraperitoneal injection of different concentrations of rBLF1 protein. The purified protein acted on A549 cells to study its cytotoxicity and the blocking effect of antibody by detecting the number of living cells with CCK-8 kit.       Results      BLF1 gene was amplified by PCR from genomic DNA of Burkholderia pseudomallei and cloned into vector pGEX-6P-2. The recombinant plasmid highly expressing GST-BLF1 protein was identified by restricting enzyme digestion, PCR and DNA sequencing. The expressed protein was about 23×103 at molecular weight . After immunization, the titer of polyclonal antibody reached 1∶1 280 000 by ELISA. A specific positive band was found in the target protein position by Western blotting. After intraperitoneal injection of rBLF1 protein, the mortality of BALB/c mice was positively correlated with the dosage of rBLF1 protein. rBLF1 protein can obviously kill A549 cells and antibodies could inhibit its role effectively.       Conclusion      Recombinant rBLF1 protein with biological activity is successfully expressed, and can effectively kill A549 cells. The protein shows cytotoxicity to normal cells, but the normal cells can tolerate the toxin to some extent. All these results provide a basis for further studying pathogenesis of Burkholderia pseudomallei, seeking active prevention and treatment measures, and widening the application of BLF1 toxin in antitumor field.

参考文献/References:

[1]Wiersinga W J, Currie B J, Peacock S J. Melioidosis[J]. N Engl J Med, 2012, 367(11): 1035-1044. DOI: 10.1056/NEJMra1204699
[2]Foong Y C, Tan M, Bradbury R S. Melioidosis: a review[J]. Rural Remote Health, 2014, 4(4): 2763.
[3]Silva E B, Dow S W. Development of Burkholderia mallei and pseudomallei vaccines[J]. Front Cell Infect Microbiol, 2013, 3: 10. DOI: 10.3389/fcimb.2013.00010
[4]毛旭虎. 加强类鼻疽的研究[J]. 第三军医大学学报, 2011, 33(13): 1315-1317. DOI: 10.16016/j.1000-5404.2011.13.013
[5]Cruz-Migoni A, Hautbergue G M, Artymiuk P J, et al. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A[J]. Science, 2011, 334(6057): 821-824. DOI: 10.1126/science.1211915
[6]Lindqvist L, Pelletier J. Inhibitors of translation initiation as cancer therapeutics[J]. Future Med Chem, 2009, 1(9): 1709-1722. DOI: 10.4155/fmc.09.122
[7]Chu J, Pelletier J. Targeting the eIF4A RNA helicase as an anti-neoplastic approach[J]. Biochim Biophys Acta, 2015, 1849(7): 781-91. DOI: 10.1016/j.bbagrm.2014.09.006
[8]Hautbergue G M, Wilson SA. BLF1, the first Burkholderia pseudomallei toxin, connects inhibition of host protein synthesis with melioidosis[J]. Biochem Soc Trans, 2012, 40(4): 842-845. DOI: 10.1042/BST20120057
[9]Fabbri A, Travaglione S, Ballan G, et al. The cytotoxic necrotizing factor 1 from E.coli: a janus toxin playing with cancer regulators[J]. Toxins (Basel), 2013, 5(8): 1462-1474. DOI: 10.3390/toxins5081462
[10]Buetow L, Flatau G, Chiu K, et al. Structure of the Rho-activating domain of Escherichia coli cytotoxic necrotizing factor 1 [J]. Nat Struct Biol, 2001, 8(7): 584-588.
[11]From S, Plusa T. Today’s threat of ricin toxin[J]. Pol Merkur Lekarski, 2015, 39(231): 162-164.
[12]Danhier F, Le-Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis [J]. Mol Pharm, 2012, 9(11): 2961-2973. DOI: 10.1021/mp3002733
[13]Fauvel B, Yasri A. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer[J]. MAbs, 2014, 6(4): 838-851. DOI: 10.4161/mabs.29089
[14]Kontermann R E, Brinkmann U. Bispecific antibody[J]. Drug Discov Today, 2015, 20(7): 838-847. DOI: 10.1016/j.drudis.2015.02.008
[15]de-Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer[J]. Cancer Lett, 2013, 332(2): 175-183. DOI: 10.1016/j.canlet.2010.11.006

更新日期/Last Update: 2016-05-29